Michele L Donato MD MBA FACP CPE

Hematologic Oncology

Chief, Stem Cell Transplantation and Cellular Therapy Program

92 2nd StreetHackensack, NJ 07601

Dr. Donato is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Donato's full profile Already have an account?

Summary

Dr. Michele Donato is an oncologist in Hackensack, NJ and is affiliated with Hackensack Meridian Health Hackensack University Medical Center. She received her medical degree from McGill University Faculty of Medicine and has been in practice 25 years. She also speaks multiple languages, including French. She specializes in hematologic oncology and is experienced in amyloidosis, hematologic oncology, myelodysplasia, myelofibrosis, and hodgkin's lymphoma.

Education & Training

University of MassachusettsMBA, 2018 - 2022
University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 1995 - 1997
McGill University Faculty of MedicineClass of 1992

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

NY State Medical License 2012 - 2028
NJ State Medical License 2005 - 2027
DC State Medical License 2004 - 2026
TX State Medical License 1997 - 2007
PA State Medical License 1996 - 1998
American Board of Internal Medicine Medical Oncology
American Association of Physician LeadersCPE

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification EpicCare Inpatient 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory EHR Suite, Epic Systems Corporation, 2014, 2016-2017
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2014, 2016-2017

Clinical Trials

High-Dose Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer Start of enrollment: 1995 Sep 01
Completed
Phase 1, Phase 2
Efficacy Study on the Strategy of HSV-Tk Engineering Donor Lymphocytes to Treat Patients With High Risk Acute Leukemia Start of enrollment: 2010 Apr 12
Terminated
Phase 3
Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma Start of enrollment: 2010 Apr 08
COMPLETED
PHASE3

Publications & Presentations

PubMed

Fluoroquinolone Prophylaxis Uncovers High Prevalence Rates of Fluoroquinolone-ResistantColonization in Multiple Myeloma Autologous Transplant Patients: A Prospective C...
Chintan Patel, Austin J Terlecky, Melissa Baker, Tara Lozy, Kelly K Yen
Cancers. 2026-05-12
2 citations
Peripheral Blood Tumor Associated Cell-Free DNA Testing as a Predictor for Relapse Postallogeneic Stem Cell Transplant for Acute Myelogenous Leukemia.
Vanisha Patel, Maciej Kabat, Andrew Ip, Sukhdeep Kaur, Hyung Chan Suh
Transplantation and Cellular Therapy. 2025-12-01
3 citations
Prospective, Randomized, Comparative Study of Myeloablative Fludarabine/Busulfan and Fludarabine/Busulfan/Total Body Irradiation Conditioning in Myeloid Diseases.
Hyung C Suh, Scott D Rowley, Sukhdeep Kaur, Brittany Lukasik, Phyllis McKiernan
Cancers. 2025-03-28

Abstracts/Posters

Engraftment Syndrome in the Setting of Autologous Stem Cell Transplantation for Multiple Myeloma-a Single Institution Review of over 600 Patients
Michele L. Donato, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Results of a Phase I Study of Pnk-007, Allogeneic, Off the Shelf NK Cell, Post Autologous Transplant in Multiple Myeloma (NCT02955550)
Michele L. Donato, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Evomela¬ Significantly Increases the Risk of Engraftment Syndrome in Patients with Multiple Myeloma Treated with Autologous Stem Cell Transplantation
Michele L. Donato, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

Elevated IL-1Ra Levels in the Stem Cell Product Is Associated with the Development of Engraftment Syndrome Following Autologous Stem Cell Transplantation for the Treat...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Phase I/II Study of Escalating Doses of Thalidomide in Conjunction with Bortezomib and High Dose Melphalan As a Conditioning Regimen for Autologous Stem Cell Transplan...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Safety and Efficacy Data for Combined Checkpoint Inhibition with Ipilimumab (Ipi) and Nivolumab (Nivo) As Consolidation Following Autologous Stem Cell Transplantation ...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Bone Marrow Transplant Program Opens at Jersey Shore University Medical CenterAugust 19th, 2022
2022 N.J. Top Cancer Doctors Deliver Quality and Compassionate Care, Close to HomeJune 16th, 2022
Philippines Again Extends COVID-19 Travel Ban on 10 Countries, Including UAE and OmanAugust 13th, 2021